首页> 外文OA文献 >P2.14-27 Efficacy and Prognostic Factor of Apatinib Plus EGFR-TKI in Treating Advanced Non-Small-Cell Lung Cancer with EGFR-TKI Resistance

【2h】

P2.14-27 Efficacy and Prognostic Factor of Apatinib Plus EGFR-TKI in Treating Advanced Non-Small-Cell Lung Cancer with EGFR-TKI Resistance

机译：P2.14-27 Apatinib Plus EGFR-TKI治疗高级非小细胞肺癌的疗效和预后因素，EGFR-TKI抗性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
G. Dong;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment [J] . Yu Yuman, Wang Yuehong, Wu Linying, Medicine. . 2021,第5期

机译：表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIS）与贝伐单抗进行高级非鳞状非小细胞肺癌患者的疗效对EGFR-TKI治疗逐渐进展
2. Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR -mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study [J] . Zhi-Yong He, Mei-Fang Li, Jing-Hui Lin, Cancer Management and Research . 2019,第2期

机译：回顾性队列研究比较了同时进行EGFR-TKI和全脑放疗与单纯EGFR-TKI作为晚期EGFR突变的非小细胞肺癌伴脑转移的一线治疗的疗效：一项回顾性队列研究
3. Comment on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC [J] . Xu Ran, Zhu Jing Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2019,第期

机译：评论：用EGFR酪氨酸激酶抑制剂治疗的晚期非小细胞肺癌患者肺炎：153例患者的META分析：NSCLC中EGFR-TKI肺炎的发病率和危险因素的荟萃分析
4. Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer [C] . Pan Jingjing, Shi Meiqi, Feng Jifeng Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012

机译：吉非替尼耐药对晚期非小细胞肺癌患者的厄洛替尼治疗效果
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations [O] . Jing-Hui Lin, Dong Lin, Ling Xu, 2017

机译：晚期非小细胞肺癌患者临床预后因素与表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）疗效的关联：回顾性评估94例EGFR突变患者
7. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations [O] . Jing-Hui Lin, Dong Lin, Ling Xu, 2016

机译：先进非小细胞肺癌患者临床预后因子和表皮生长因子受体 - 酪氨酸激酶抑制剂（EGFR-TKI）疗效的关联：EGFR突变94例回顾性评估

P2.14-27 Efficacy and Prognostic Factor of Apatinib Plus EGFR-TKI in Treating Advanced Non-Small-Cell Lung Cancer with EGFR-TKI Resistance

著录项

引文网络

相似文献

相关主题

期刊订阅